Halozyme Therapeutics, Inc. Stock News

SAN DIEGO , Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the executive leadership team are scheduled to present and host investor meetings at the following investor conferences.  Details on the presentations are as follows: Event: Piper Sandler 36th Annual Healthcare Conference Presenter: Nicole LaBrosse, Chief Financial O...

The top five biotech stocks today have several commonalities. Among them are strong ratings.

Halozyme Therapeutics said on Friday it had withdrawn its proposal to acquire Evotec SE for 2 billion euros ($2.09 billion) after the German drug developer was unwilling to engage in discussions.

SAN DIEGO , Nov. 22, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion.   Helen Torley, president and chief executive officer of Halozyme , shared the following stat...

HAMBURG - Keine Übernahme: Der US-Wirkstoffforscher Halozyme US40637H1095 will sich nun doch nicht mehr den Evotec-Konzern DE0005664809 einverleiben.

Keine Übernahme: Das US-Wirkstoffforscher Halozyme US40637H1095 will sich nun doch nicht mehr den Evotec-Konzern DE0005664809 einverleiben.

Keine Übernahme: Der US-Wirkstoffforscher Halozyme US40637H1095 will sich nun doch nicht mehr den Evotec-Konzern DE0005664809 einverleiben.

In einem möglichen Abwehrkampf gegen eine Übernahme durch das US-Unternehmen Halozyme US40637H1095 setzt der Wirkstoffforscher Evotec DE0005664809 auf seine Autonomie.